People: Aastrom Biosciences Inc (ASTM.O)

ASTM.O on Consolidated Issue listed on NASDAQ Capital Market

3.34USD
24 Jul 2014
Price Change (% chg)

$0.01 (+0.30%)
Prev Close
$3.33
Open
$3.31
Day's High
$3.39
Day's Low
$3.28
Volume
51,363
Avg. Vol
213,001
52-wk High
$17.79
52-wk Low
$3.09

Search Stocks

Zerbe, Robert 

Brief Biography

Dr. Robert L. Zerbe, M.D., is Independent Chairman of the Board of Aastrom Biosciences, Inc. He has been a Director since January 2006 and Chairman of the Board of Directors since October 2012, is the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company which he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with pharmaceutical companies including Eli Lilly (from 1982 to 1993) and Pfizer (formerly Parke-Davis) (from 1993 to 2000). During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity he led the clinical development programs for a number of key products, including Lipitor ® and Neurontin ®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Dr. Zerbe currently serves on the board of directors of Optimer Pharmaceuticals, Inc. (since 2009), a biopharmaceutical company. He also serves on the board of directors of, Edgemont Pharmaceuticals, a private specialty pharma company.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Search Stocks